Compare Goldman Sachs Group Inc (GS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs GeneDx Holdings Corp — how do they compare? Goldman Sachs Group Inc trades at $895.32 (market cap $256.98B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Goldman Sachs Group Inc is far larger — about 127.2× GeneDx Holdings Corp's market cap, and Goldman Sachs Group Inc pays a 2.27% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Goldman Sachs Group Inc for 101 Days and GeneDx Holdings Corp for 19 Days on average.
| GS | WGS | |
|---|---|---|
Market Cap | $256.98B | $2.02B |
Volume | 1,748,426 | 734,640 |
Sector | Financials | Health |
52-Week High | $1.15K | $167.51 |
52-Week Low | $744.60 | $34.51 |
Typical Hold Time | 101 Days | 19 Days |
Enterprise Value | $814.98B | $2.05B |
Dividend Yield | 2.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $882.59, down 0.52% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company shows strong profitability with a 31.68% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights CEO David Solomon's focus on expanding earnings and building a durable revenue base, while the FICC business is expected to soften in Q3 2026.
The stock presents a mixed outlook: attractive valuation with a P/E of 13.63 and consensus price target of $1,130 suggests upside, but negative operating cash flows and high debt levels pose risks. Analyst sentiment is cautious with 40% buy ratings, while institutional interest remains steady. Key catalysts include revenue growth in asset and wealth management, but macroeconomic volatility and competitive pressures could hinder performance.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
